A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population

Pharmacogenomics. 2015 Nov;16(17):1943-9. doi: 10.2217/pgs.15.133. Epub 2015 Nov 10.

Abstract

Aim: We carried out a pharmacogenomic study in order to identify susceptible genes for antipsychotics induced weight gain within the Chinese Han population.

Materials & methods: We enrolled 216 patients with schizophrenia in our study. All of them underwent risperidone monotherapy, and fulfilled 4-week follow-up. Weight gain was measured before treatment and 4 weeks later. Seven hundred and sixty-eight SNPs from 85 genes were calculated for association with weight gain percentage.

Results: Fifty-seven SNPs located at 16 genes with a p-value less than 0.05.4 SNPs located on serotonin transporter gene (solute carrier family 6, member 4, SLC6A4) remained significant after multitest correction (rs3813034, p = 0.000357, q = 0.08, rs1042173, rs4325622, rs9303628, p = 0.000451, q = 0.08).

Conclusion: SLC6A4 might be susceptible gene for risperidone-induced weight gain within the Chinese Han population.

Keywords: pharmacogenomic; risperidone-induced weight gain; serotonin transporter gene (solute carrier family 6, member 4, SLC6A4).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Asian People / genetics*
  • China
  • Female
  • Follow-Up Studies
  • Genetic Association Studies / methods
  • Humans
  • Male
  • Polymorphism, Single Nucleotide / genetics
  • Risperidone / adverse effects*
  • Schizophrenia / drug therapy
  • Schizophrenia / genetics
  • Serotonin Plasma Membrane Transport Proteins / genetics*
  • Weight Gain / drug effects
  • Weight Gain / genetics*
  • Young Adult

Substances

  • Antipsychotic Agents
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins
  • Risperidone